

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***Complete if known*

Application Number	10/016,726
Filing Date	10/30/01
First Named Inventor	Zayas
Group Art Unit	1614
Examiner Name	Kevin E. Weddington
Attorney Docket Number	ALPHA-0200

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U. S. Patent Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number		
Ke	AA	5,294,645	Chastain, <i>et al.</i>	03-15-1994
Ke	AB	5,411,992	Eini, <i>et al.</i>	05-02-1995
Ke	AC	5,763,415	Sukumar	06-09-1998
	AD			
	AE			
	AF			
	AG			
	AH			
	AI			
	AJ			
	AK			
	AL			
	AM			
	AN			
	AO			
	AP			
	AQ			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Documents MM- DD-YYYY
		Country	Number		
	BA				
	BB				
	BC				
	BD				
	BE				
	BF				
	BG				
	BH				
	BI				
	BJ				

Examiner Initials	60 Weddington	Date Considered	8-8-01
----------------------	---------------	--------------------	--------

ALPHA-0200

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***Complete If Known*

Application Number	10/016,726
Filing Date	10/30/01
First Named Inventor	Zayas
Group Art Unit	1614
Examiner Name	Kevin E. Weddington
Attorney Docket Number	ALPHA-0200

Sheet

2

of

2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTER), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page (s), volume-issue number(s), publisher, city and/or country where published.
WJ		
WJ	CA	PAMELA L. CROWELL, REBEKAH R. CHANG, ZHIBIN REN, CHARLES E. ELSON, and MICHAEL N. GOULD; <i>Selective Inhibition of Isoprenylation of 21-26-kDa Proteins by the Anticarcinogen d-Limonene and its Metabolites</i> ; <u>The Journal of Biological Chemistry</u> ; 1991; Vol. 266, No. 26, pp. 17679, 17681-17685; USA
WJ	CB	JILL D. HAAG, MARY J. LINDSTROM, AND MICHAEL N. GOULD; <i>Limonene-induced Regression of Mammary Carcinomas</i> ; <u>Cancer Research</u> ; 1992; pp. 4021-4026; USA
WJ	CC	BANDARU S. REDDY, C-X. WANG, HANAN SAMAHA, RONALD LUBET, VERNON E. STEELE, GARY J. KELLOFF, and CHINTHALAPALLY V. RAE; <i>Chemoprevention of Colon Carcinogenesis by Dietary Perillyl Alcohol</i> ; <u>Cancer Research</u> ; 1997; pp. 420-425; USA
WJ	CD	GREGORY H. RIPPLE, MICHAEL N. GOULD, JAMES A. STEWART, KENDRA D. TUTSCH, RHODA Z. ARZOOMANIAN, DONA ALBERTI, CHRIS FEIERABEND, MARCIA POMPLUN, GEORGE WILDING, and HOWARD H. BAILEY; <i>Phase I Clinical Trial of Perillyl Alcohol Administered Daily</i> ; <u>Clinical Cancer Research</u> ; 1998; pp 1159-1164; USA
WJ	CE	MARGARET BARTHELMAN, WEIXING CHEN, HELEN L. GENSLER, CHUANSHU HUANG, ZIGANG DONG, and G. TIM BOWDEN; <i>Inhibitory Effects of Perillyl Alcohol on UVB-induced Murine Skin Cancer and AP-1 Transactivation</i> ; <u>Cancer Research</u> ; 1998; pp. 711-716; USA
WJ	CF	PIET J. M. BOON, DENNIS VAN DER BOON, and GERARD J. MULDER; <i>Cytotoxicity and Biotransformation of the Anticancer Drug Perillyl Alcohol in PC12 Cells and in the Rat</i> ; <u>Toxicology and Applied Pharmacology</u> ; 2000; pp. 55-61; USA
WJ	CG	GREGORY H. RIPPLE, MICHAEL N. GOULD, RHODA Z. ARZOOMANIAN, DONA ALBERTI, CHRIS FEIERABEND, KRIS SIMON, KIM BINGER, KENDRA D. TUTSCH, MARCIA POMPLUN, ANY WAHAMAKI, REBECCA, MARNOCHA, GEORGE WILDING, and HOWARD H. BAILEY; <i>Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four Times a Day</i> ; <u>Clinical Cancer Research</u> ; 2000; pp. 390-396; USA
WJ	CH	GARY R. HUDES, CHRISTINE E. SZARKA, ANDREA ADAMS, SULABHA RANGANATHAN, ROBERT A. McCAULEY, LOUIS M. WEINER, COREY J. LANGER, SAMUEL LITWIN, GWEN YESLOW, THERESA HALBERR, MINGXIN QIAN, and JAMES M. GALLO; <i>Phase I Pharmacokinetic Trial of Perillyl Alcohol (NSC 641066 in Patients with Refractory Solid Malignancies</i> ; <u>Clinical Cancer Research</u> ; 2000; pp. 3071-3080; USA

Examiner
SignatureDate
Considered

8-8-02